US Stock Market News · Opening Bell

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE
LATHAM, N.Y., October 21, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced two milestones for irreversible electroporation (IRE), the non-thermal ablation technology delivered by the NanoKnife System. The first is the publication of results from the DIRECT study in The Oncologist, in
Yahoo08:306 Days AgoANGO+0.7%

04:00Oct 211 Story

AngioDynamics Reports DIRECT Study Findings Showing Longer Overall Survival In Stage III Pancreatic Ductal Adenocarcinoma, Gets Category I CPT Code For Open IRE Ablation Of Pancreatic Tumors, Effective January 1, 2027
Prospective, multicenter FDA IDE study found an IRE-based treatment strategy was associated with longer overall survival in Stage III pancreatic cancer; new Category I CPT code for open pancreatic IRE takes effect
Benzinga04:43ANGO+0.7%

09:00Oct 151 Story

AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist
AngioDynamics, Inc. stock analysis: AlphaVac, Auryon, NanoKnife growth vs execution risk and margin swings. Click for this updated look at ANGO prospects.
SeekingAlpha09:27ANGO+0.7%

09:00Oct 131 Story

HC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18
HC Wainwright & Co. analyst Yi Chen maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $19 to $18.
Benzinga09:09ANGO+0.7%

09:00Oct 91 Story

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
AngioDynamics beats first-quarter earnings estimates as revenues rise 6.9% on strong Med Tech growth, with margin expansion and robust Auryon and NanoKnife sales.
Yahoo09:58ANGO+0.7%

12:00-23:00Oct 82 Stories

11:00Oct 81 Story

Why AngioDynamics Crashed Today
AngioDynamics beats earnings, and drops 20%.
Yahoo11:11ANGO+0.7%

06:00-09:00Oct 22 Stories

16:00Sep 281 Story

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026
LATHAM, N.Y., September 28, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2027 before the market open on Thursday, October 8, 2026. The Company’s management will host a conference call at 8:00 am ET the same day to discuss the results.
Yahoo16:30ANGO+0.7%

News

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

04:00Oct 211 Story

AngioDynamics Reports DIRECT Study Findings Showing Longer Overall Survival In Stage III Pancreatic Ductal Adenocarcinoma, Gets Category I CPT Code For Open IRE Ablation Of Pancreatic Tumors, Effective January 1, 2027

09:00Oct 151 Story

AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist

09:00Oct 131 Story

HC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18

09:00Oct 91 Story

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

12:00-23:00Oct 82 Stories

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics, Inc. Q1 2027 Earnings Call Summary

11:00Oct 81 Story

Why AngioDynamics Crashed Today

06:00-09:00Oct 22 Stories

Delta Stock Struggles As Revenue Growth Accelerates; Will Its Results Pass Muster?

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

16:00Sep 281 Story

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026

AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE

04:00Oct 211 Story

AngioDynamics Reports DIRECT Study Findings Showing Longer Overall Survival In Stage III Pancreatic Ductal Adenocarcinoma, Gets Category I CPT Code For Open IRE Ablation Of Pancreatic Tumors, Effective January 1, 2027

09:00Oct 151 Story

AngioDynamics: Progress Evident, But Volatility And Margin Concerns Persist

09:00Oct 131 Story

HC Wainwright & Co. Maintains Buy on AngioDynamics, Lowers Price Target to $18

09:00Oct 91 Story

ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y

12:00-23:00Oct 82 Stories

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics, Inc. Q1 2027 Earnings Call Summary

11:00Oct 81 Story

Why AngioDynamics Crashed Today

06:00-09:00Oct 22 Stories

Delta Stock Struggles As Revenue Growth Accelerates; Will Its Results Pass Muster?

AngioDynamics and The PERT Consortium® Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence

16:00Sep 281 Story

AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026